Dendritic cells

An important link between antiphospholipid antibodies, endothelial dysfunction, and atherosclerosis in autoimmune and non-autoimmune diseases

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The presence of dendritic cells, antigen-presenting cells that link innate and adaptive immunity, is necessary to generate and maintain the production of antiphospholipid antibodies in response to exposed intracellular phospholipids on the outer surface of apoptotic cells. In turn, antiphospholipid antibodies enhance dendritic cell-induced inflammatory and proatherogenic responses in a number of conditions that are associated with accelerated atherosclerosis, including diabetes, chronic kidney disease, periodontal infections, and aging. While altering dendritic cells by modifying the ubiquitin-proteasome system enhances antiphospholipid antibody production and leads to development of accelerated atherosclerosis and autoimmune features, inducing tolerance by dendritic cell manipulation leads to decreased atherosclerosis and thrombosis. Therefore, further translational studies are needed to understand the interplay between dendritic cells and antiphospholipid antibodies, and to develop potential new therapies for antiphospholipid syndrome and atherosclerosis. Here we review current experimental and translational studies that have examined the role of dendritic cells in antiphospholipid antibody formation and in antiphospholipid-associated atherosclerosis and thrombosis.

Original languageEnglish (US)
Pages (from-to)197-206
Number of pages10
JournalClinical Immunology
Volume146
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Antiphospholipid Antibodies
Dendritic Cells
Atherosclerosis
Antibody Formation
Thrombosis
Antiphospholipid Syndrome
Adaptive Immunity
Antigen-Presenting Cells
Proteasome Endopeptidase Complex
Ubiquitin
Chronic Renal Insufficiency
Innate Immunity
Phospholipids
Infection

Keywords

  • Antiphospholipid antibodies
  • Antiphospholipid syndrome
  • Atherosclerosis
  • Dendritic cells

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

@article{a103092bb3a54b07abc8f991bd485966,
title = "Dendritic cells: An important link between antiphospholipid antibodies, endothelial dysfunction, and atherosclerosis in autoimmune and non-autoimmune diseases",
abstract = "The presence of dendritic cells, antigen-presenting cells that link innate and adaptive immunity, is necessary to generate and maintain the production of antiphospholipid antibodies in response to exposed intracellular phospholipids on the outer surface of apoptotic cells. In turn, antiphospholipid antibodies enhance dendritic cell-induced inflammatory and proatherogenic responses in a number of conditions that are associated with accelerated atherosclerosis, including diabetes, chronic kidney disease, periodontal infections, and aging. While altering dendritic cells by modifying the ubiquitin-proteasome system enhances antiphospholipid antibody production and leads to development of accelerated atherosclerosis and autoimmune features, inducing tolerance by dendritic cell manipulation leads to decreased atherosclerosis and thrombosis. Therefore, further translational studies are needed to understand the interplay between dendritic cells and antiphospholipid antibodies, and to develop potential new therapies for antiphospholipid syndrome and atherosclerosis. Here we review current experimental and translational studies that have examined the role of dendritic cells in antiphospholipid antibody formation and in antiphospholipid-associated atherosclerosis and thrombosis.",
keywords = "Antiphospholipid antibodies, Antiphospholipid syndrome, Atherosclerosis, Dendritic cells",
author = "Broder, {Anna R.} and Chan, {Jimmy J.} and Chaim Putterman",
year = "2013",
month = "3",
doi = "10.1016/j.clim.2012.12.002",
language = "English (US)",
volume = "146",
pages = "197--206",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Dendritic cells

T2 - An important link between antiphospholipid antibodies, endothelial dysfunction, and atherosclerosis in autoimmune and non-autoimmune diseases

AU - Broder, Anna R.

AU - Chan, Jimmy J.

AU - Putterman, Chaim

PY - 2013/3

Y1 - 2013/3

N2 - The presence of dendritic cells, antigen-presenting cells that link innate and adaptive immunity, is necessary to generate and maintain the production of antiphospholipid antibodies in response to exposed intracellular phospholipids on the outer surface of apoptotic cells. In turn, antiphospholipid antibodies enhance dendritic cell-induced inflammatory and proatherogenic responses in a number of conditions that are associated with accelerated atherosclerosis, including diabetes, chronic kidney disease, periodontal infections, and aging. While altering dendritic cells by modifying the ubiquitin-proteasome system enhances antiphospholipid antibody production and leads to development of accelerated atherosclerosis and autoimmune features, inducing tolerance by dendritic cell manipulation leads to decreased atherosclerosis and thrombosis. Therefore, further translational studies are needed to understand the interplay between dendritic cells and antiphospholipid antibodies, and to develop potential new therapies for antiphospholipid syndrome and atherosclerosis. Here we review current experimental and translational studies that have examined the role of dendritic cells in antiphospholipid antibody formation and in antiphospholipid-associated atherosclerosis and thrombosis.

AB - The presence of dendritic cells, antigen-presenting cells that link innate and adaptive immunity, is necessary to generate and maintain the production of antiphospholipid antibodies in response to exposed intracellular phospholipids on the outer surface of apoptotic cells. In turn, antiphospholipid antibodies enhance dendritic cell-induced inflammatory and proatherogenic responses in a number of conditions that are associated with accelerated atherosclerosis, including diabetes, chronic kidney disease, periodontal infections, and aging. While altering dendritic cells by modifying the ubiquitin-proteasome system enhances antiphospholipid antibody production and leads to development of accelerated atherosclerosis and autoimmune features, inducing tolerance by dendritic cell manipulation leads to decreased atherosclerosis and thrombosis. Therefore, further translational studies are needed to understand the interplay between dendritic cells and antiphospholipid antibodies, and to develop potential new therapies for antiphospholipid syndrome and atherosclerosis. Here we review current experimental and translational studies that have examined the role of dendritic cells in antiphospholipid antibody formation and in antiphospholipid-associated atherosclerosis and thrombosis.

KW - Antiphospholipid antibodies

KW - Antiphospholipid syndrome

KW - Atherosclerosis

KW - Dendritic cells

UR - http://www.scopus.com/inward/record.url?scp=84873879763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873879763&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2012.12.002

DO - 10.1016/j.clim.2012.12.002

M3 - Article

VL - 146

SP - 197

EP - 206

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 3

ER -